Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
111.01
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Jan 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
9,971
Open
111.01
Bid (Size)
110.37 (100)
Ask (Size)
110.89 (700)
Prev. Close
111.01
Today's Range
111.01 - 111.01
52wk Range
73.31 - 112.90
Shares Outstanding
2,531,374,696
Dividend Yield
3.06%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen)
↗
Today 6:49 EST
Via
Chartmill
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
January 14, 2026
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period...
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Performance
YTD
+4.3%
+4.3%
1 Month
+10.7%
+10.7%
3 Month
+32.0%
+32.0%
6 Month
+34.7%
+34.7%
1 Year
+11.4%
+11.4%
More News
Read More
Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Value Investment Case
↗
January 14, 2026
Via
Chartmill
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
January 12, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
World Trade
Merck In Talks To Acquire Revolution Medicines For About $30B: Report
↗
January 09, 2026
Via
Stocktwits
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B
↗
January 12, 2026
Via
Stocktwits
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
January 12, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Intellectual Property
3 Dividend Stocks to Hold for the Next 10 Years
↗
January 12, 2026
Via
The Motley Fool
Topics
Bonds
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report
↗
January 08, 2026
Via
Stocktwits
1 Momentum Stock Worth Your Attention and 2 Facing Headwinds
January 11, 2026
Via
StockStory
This ETF Is Proof That the Healthcare Rebound Is Real
↗
January 11, 2026
Via
MarketBeat
Topics
ETFs
Why Revolution Medicines Stock Surged by 11% Today
↗
January 09, 2026
Via
The Motley Fool
Topics
Intellectual Property
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
January 09, 2026
Via
MarketMinute
Topics
Intellectual Property
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
January 09, 2026
Via
PredictStreet
Topics
Initial Public Offering
Intellectual Property
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
↗
January 09, 2026
Via
Benzinga
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs
↗
January 08, 2026
Via
Stocktwits
Topics
Government
American Trade Resilience: Deficit Hits 17-Year Low as Export Surge and Tariff Shocks Reshape Global Commerce
January 08, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Energy
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
January 08, 2026
Via
MarketMinute
Topics
Intellectual Property
Neogen Shares Skyrocket as Q2 Earnings Beat Signals Turning Point in 3M Integration Strategy
January 08, 2026
Via
MarketMinute
Topics
Earnings
Economy
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
January 07, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
January 07, 2026
Via
MarketMinute
Topics
Economy
3 Drug Stocks to Buy at a Discount
↗
January 07, 2026
Via
The Motley Fool
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
January 07, 2026
Via
PredictStreet
Topics
Economy
Initial Public Offering
Intellectual Property
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
January 07, 2026
From
Merck & Co., Inc.
Via
Business Wire
Merck to Complete Acquisition of Cidara Therapeutics
January 07, 2026
From
Merck Sharp & Dohme
Via
Business Wire
Frequently Asked Questions
Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 111.01
When was Merck & Co last traded?
The last trade of Merck & Co was at 01/14/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 281.01B
How many shares of Merck & Co are outstanding?
Merck & Co has 281B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.